Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10926 - 10950 of 11653 in total
Olaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).
Investigational
Matched Description: … Olaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer …
Orforglipron is under investigation in clinical trial NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes).
Investigational
Matched Description: … Orforglipron is under investigation in clinical trial NCT06010004 (A Long-term Safety Study of Orforglipron …
Eltrekibart is under investigation in clinical trial NCT06046729 (A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa).
Investigational
Matched Description: … Eltrekibart is under investigation in clinical trial NCT06046729 (A Study of Eltrekibart (LY3041658) …
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain .
Experimental
Matched Description: … Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain [A174817 …
Poseltinib is under investigation in clinical trial NCT02628028 (A Study of LY3337641 in Rheumatoid Arthritis).
Investigational
Matched Description: … Poseltinib is under investigation in clinical trial NCT02628028 (A Study of LY3337641 in Rheumatoid Arthritis …
NC-6300, also known as K-912, is a novel epirubicin drug-conjugated polymeric micelle.
Investigational
Matched Description: … NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle. …
EXT608 is a long-acting PTH derivative under investigation for the treatment of hyperparathyroidism.
Investigational
Matched Description: … EXT608 is a long-acting PTH derivative under investigation for the treatment of hyperparathyroidism. …
Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.
Experimental
Matched Description: … Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan. …
99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in...
Investigational
Matched Description: … 99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging …
KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. While effective, disease progression may occur 6 to 8 months...
Investigational
Matched Description: … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors ( …
Investigational
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... MB07811, a small molecule that is administered orally, has been extensively studied preclinically and ... MB07811 combines a novel thyroid hormone receptor agonist with the Company's novel HepDirect liver targeting …
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a ... pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a ... These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, …
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … XL820 is a solid. ... receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate …
Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent. Cirazoline has also been shown to decrease food...
Experimental
Matched Description: … Cirazoline acts on a number of α adrenergic receptors. ... It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. …
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture. The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID ... As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908 …
COVID-19 convalescent plasma is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. Immunitor Inc., the sponsor, is currently testing this oral...
Investigational
Matched Description: … the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a ... concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a
Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.
Experimental
Matched Description: … Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a
Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen).
Investigational
Matched Description: … clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Description: … Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single …
Displaying drugs 10926 - 10950 of 11653 in total